[go: up one dir, main page]

UY34916A - "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético" - Google Patents

"preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"

Info

Publication number
UY34916A
UY34916A UY0001034916A UY34916A UY34916A UY 34916 A UY34916 A UY 34916A UY 0001034916 A UY0001034916 A UY 0001034916A UY 34916 A UY34916 A UY 34916A UY 34916 A UY34916 A UY 34916A
Authority
UY
Uruguay
Prior art keywords
solid preparation
metilsulfonil
bifenil
propoxi
dimetil
Prior art date
Application number
UY0001034916A
Other languages
English (en)
Inventor
Hoshina Wataru
Mima Yasushi
Hohokabe Miyuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34916A publication Critical patent/UY34916A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una preparación sólida superior en la propiedad de desintegración y estabilidad de preservación. La presente invención se refiere a una preparación sólida que contiene (1) el compuesto (A) o una de sus sales, (2) metformina o una de sus sales y (3) crospovidona. También se refiere a un compuesto (A) o una de sus sales superiores en la propiedad de disolución.
UY0001034916A 2012-07-19 2013-07-17 "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético" UY34916A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012161025A JP2015127299A (ja) 2012-07-19 2012-07-19 固形製剤

Publications (1)

Publication Number Publication Date
UY34916A true UY34916A (es) 2014-02-28

Family

ID=48980240

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034916A UY34916A (es) 2012-07-19 2013-07-17 "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"

Country Status (5)

Country Link
JP (1) JP2015127299A (es)
AR (1) AR092351A1 (es)
TW (1) TW201408290A (es)
UY (1) UY34916A (es)
WO (1) WO2014014129A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2021104941A (ja) * 2019-12-26 2021-07-26 ニプロ株式会社 薬物高含有量錠剤及びその製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2006112549A1 (ja) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited 縮合複素環化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
BRPI0615150A2 (pt) 2005-08-10 2017-06-20 Takeda Pharmaceuticals Co agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP4401428B2 (ja) 2006-06-27 2010-01-20 武田薬品工業株式会社 縮合環化合物
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
MY158052A (en) 2006-10-19 2016-08-30 Takeda Pharmaceutical Indole compound
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
JP2012161025A (ja) 2011-02-02 2012-08-23 Mitsubishi Electric Corp ケーブル診断装置及びケーブル診断方法

Also Published As

Publication number Publication date
JP2015127299A (ja) 2015-07-09
WO2014014129A1 (en) 2014-01-23
AR092351A1 (es) 2015-04-15
TW201408290A (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
CO6511251A2 (es) Compuestos quimicos
CL2016002970A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo.
CY1123456T1 (el) Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
CO6420351A2 (es) Composiciones plaguicidas
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
CO6331463A2 (es) Nuevos derivados de triazolo(4,3-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
CO6741154A2 (es) Compuestos de triazolopiridina
UY32126A (es) Composición farmacéutica sólida
MX2016009049A (es) Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
ECSP11011224A (es) Derivados de tiadiazoles y oxadiazoles, su preparaciòn y su aplicaciòn en terapia
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
AR089486A1 (es) PREPARACION FARMACEUTICA QUE COMPRENDE b-CICLODEXTRINA SUSTITUIDA
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"
NI201100051A (es) Sales de n - [ 6 - ( cis - 2, 6 - dimetil - morfolin - 4 - il ) - piridin - 3 - il ] - 2 - metil - 4' - ( trifluoro - metoxi ) - [ 1, 1' - bifenil] - 3 - carboxamida.
BR112016006153A2 (pt) composição contendo polietileno glicol
UA103290C2 (ru) Фармацевтическая композиция ибупрофена для инъекции
ES2585558T3 (es) Uso de sales de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio en el tratamiento de una enfermedad cardiovascular
UY32333A (es) Derivados cuaternarios de piridina y utilización de los mismos
ES2513569T3 (es) Formulación de liberación prolongada que comprende un derivado de metastina
TH129179A (th) อนุพันธ์ของพิแรโซล, การเตรียมของมันและการใช้เชิงรักษาของมัน
TH156221A (th) 4-(8-เมธอกซิ-1-((1-เมธอกซิโพรเพน-2-อิล)-2-(เททราไฮโดร-2h-ไพแรน-4-อิล)-1h-อิมิแดโซ[4.5-c]-ควิโนลิน-7-อิล)-3,5-ไดเมธิลไอโซซาโซล และการใช้ของมันเป็นตัวยับยั้งโบรโมโดเมน

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20140715